NASDAQ:TCRT Alaunos Therapeutics (TCRT) Stock Price, News & Analysis $0.91 +0.03 (+2.99%) As of 03:01 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About Alaunos Therapeutics Stock (NASDAQ:TCRT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Alaunos Therapeutics alerts:Sign Up Key Stats Today's Range$0.89▼$0.9550-Day Range$0.89▼$2.0252-Week Range$0.85▼$4.59Volume31,016 shsAverage Volume280,272 shsMarket Capitalization$2.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Alaunos Therapeutics, Inc. was a clinical-stage biotechnology company focused on developing genetically engineered T-cell therapies for cancer. Its primary research centered on T-cell receptor (TCR) therapies designed to recognize cancer-associated antigens and target solid tumors, an area that has historically been challenging for cell therapy developers. The company’s technology portfolio included the Sleeping Beauty nonviral gene-transfer system, which was intended to introduce tumor-targeting TCRs into a patient’s T cells. Alaunos also pursued personalized therapies targeting tumor-specific mutations, commonly known as neoantigens, and evaluated its programs through collaborations and clinical research involving academic and medical institutions, including the National Cancer Institute. Alaunos was formerly known as Ziopharm Oncology and adopted its current name in 2022. The company was headquartered in Houston, Texas, and its programs were primarily directed toward patients with advanced cancers in the United States. Alaunos subsequently reduced operations and reassessed its development strategy, and publicly available information about its ongoing programs and leadership is limited.AI Generated. May Contain Errors. Read More Alaunos Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks20th Percentile Overall ScoreTCRT MarketRank™: Alaunos Therapeutics scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingAlaunos Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageAlaunos Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Alaunos Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Alaunos Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alaunos Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlaunos Therapeutics has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Alaunos Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.29% of the float of Alaunos Therapeutics has been sold short.Short Interest Ratio / Days to CoverAlaunos Therapeutics has a short interest ratio ("days to cover") of 0.59, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alaunos Therapeutics has recently increased by 6.45%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlaunos Therapeutics does not currently pay a dividend.Dividend GrowthAlaunos Therapeutics does not have a long track record of dividend growth. News and Social Media4.2 / 5News SentimentN/A News SentimentAlaunos Therapeutics has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Alaunos Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for TCRT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Alaunos Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Alaunos Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders16.14% of the stock of Alaunos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions27.72% of the stock of Alaunos Therapeutics is held by institutions.Read more about Alaunos Therapeutics' insider trading history. Receive TCRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alaunos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TCRT Stock News HeadlinesAlaunos Therapeutics Announces New Registered Direct OfferingSeptember 22, 2026 | tipranks.comAlaunos Prices $1.12M Registered Direct OfferingSeptember 19, 2026 | rttnews.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 1 at 1:00 AM | Stansberry Research (Ad)Alaunos Therapeutics Stock Falls 17% After Public Offering AnnouncementSeptember 19, 2026 | rttnews.comAlaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rulesSeptember 18, 2026 | globenewswire.comWhy Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving PremarketSeptember 18, 2026 | benzinga.comAlaunos Therapeutics Updates Bylaws to Ease Shareholder QuorumSeptember 17, 2026 | tipranks.comAlaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse StudyJune 29, 2026 | markets.businessinsider.comSee More Headlines TCRT Stock Analysis - Frequently Asked Questions How have TCRT shares performed this year? Alaunos Therapeutics' stock was trading at $3.23 at the start of the year. Since then, TCRT shares have decreased by 71.7% and is now trading at $0.9140. How were Alaunos Therapeutics' earnings last quarter? Alaunos Therapeutics, Inc. (NASDAQ:TCRT) released its earnings results on Friday, August, 14th. The company reported ($0.41) earnings per share for the quarter. When did Alaunos Therapeutics' stock split? Alaunos Therapeutics shares reverse split on the morning of Thursday, July 18th 2024.The 1-10 reverse split was announced on Thursday, July 18th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Alaunos Therapeutics? Shares of TCRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alaunos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alaunos Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AUO (AUOTY), DiamondRock Hospitality (DRH), American Water Works (AWK) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/14/2026Today10/01/2026Next Earnings (Estimated)11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 TCRT's financial health is in the Yellow zone, according to TradeSmith. TCRT has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TCRT CIK1107421 Webwww.alaunos.com Phone(346) 355-4099Fax617-241-2855Employees1Year Founded2005Profitability EPS (Trailing Twelve Months)($1.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.18 million Net MarginsN/A Pretax Margin-133,666.67% Return on Equity-232.60% Return on Assets-158.99% Debt Debt-to-Equity RatioN/A Current Ratio0.77 Quick Ratio0.77 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.93 per share Price / Book0.98Miscellaneous Outstanding Shares2,540,000Free Float2,130,000Market Cap$2.32 million OptionableNo Data Beta-0.97 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:TCRT) was last updated on 10/1/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alaunos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alaunos Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
